{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T07:55:32Z","timestamp":1792569332568,"version":"4.5.0"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["journalofclinicalvirology.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Virology"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1016\/j.jcv.2018.06.012","type":"journal-article","created":{"date-parts":[[2018,6,21]],"date-time":"2018-06-21T18:19:55Z","timestamp":1529605195000},"page":"112-117","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Dolutegravir (DTG)-containing regimens after receiving raltegravir (RAL) or elvitegravir (EVG): Durability and virological response in a large Italian HIV drug resistance network (ARCA)"],"prefix":"10.1016","volume":"105","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0375-9990","authenticated-orcid":false,"given":"S.","family":"Rusconi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Adorni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Tau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Borghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Pecorari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Maserati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Francisci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Monno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Punzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Meraviglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Paolucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Di Biagio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Bruzzone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Mancon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Micheli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0344-6281","authenticated-orcid":false,"given":"M.","family":"Zazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcv.2018.06.012_bib0005","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s12977-017-0360-7","article-title":"HIV drug resistance against strand transfer integrase inhibitors","volume":"14","author":"Anstett","year":"2017","journal-title":"Retrovirology"},{"key":"10.1016\/j.jcv.2018.06.012_bib0010","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1097\/QAD.0b013e3283612419","article-title":"For the SPRING-1 team. Dolutegravir in antiretroviral-naive adults with HIV-1: 96-week results from a randomized dose-ranging study","volume":"27","author":"Stellbrink","year":"2013","journal-title":"AIDS"},{"key":"10.1016\/j.jcv.2018.06.012_bib0015","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/S1473-3099(13)70257-3","article-title":"For the extended SPRING-2 study group. Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, doubleblind, non-inferiority trial","volume":"13","author":"Raffi","year":"2013","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.jcv.2018.06.012_bib0020","article-title":"Dolutegravir regimen statistically superior to efavirenz\/tenofovir\/emtricitabine: 96-week results from the SINGLE study (ING114467), Boston, MA, USA; March 3\u20136","author":"Walmsley","year":"2014","journal-title":"21st Conference on Retroviruses and Opportunistic Infections"},{"key":"10.1016\/j.jcv.2018.06.012_bib0025","doi-asserted-by":"crossref","first-page":"e127","DOI":"10.1016\/S2352-3018(15)00027-2","article-title":"Once-daily dolutegravir versus darunavir plus ritonavir for treatment-naive adults with HIV-1 infection (FLAMINGO): 96 week results from a randomised, open-label, phase 3b study","volume":"2","author":"Molina","year":"2015","journal-title":"Lancet HIV"},{"key":"10.1016\/j.jcv.2018.06.012_bib0030","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1093\/infdis\/jis750","article-title":"Safety and efficacy of dolutegravir in treatment-experienced subjects with raltegravir-resistant HIV type 1 infection: 24-week results of the VIKING study","volume":"207","author":"Eron","year":"2013","journal-title":"J Infect. Dis."},{"key":"10.1016\/j.jcv.2018.06.012_bib0035","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1093\/infdis\/jiu051","article-title":"Dolutegravir in antiretroviral-experienced patients with raltegravir- and\/or elvitegravir-resistant HIV-1: 24-week results of the phase III VIKING-3 study","volume":"210","author":"Castagna","year":"2014","journal-title":"J Infect. Dis."},{"key":"10.1016\/j.jcv.2018.06.012_bib0040","series-title":"Superior Efficacy of Dolutegravir (DTG) Plus 2 Nucleoside Reverse Transcriptase Inhibitors (NRTIs) Compared With Lopinavir\/Ritonavir (LPV\/RTV) Plus 2 NRTIs in Second-Line Treatment: Interim Data From the DAWNING Study","author":"Aboud","year":"2017"},{"key":"10.1016\/j.jcv.2018.06.012_bib0045","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/S0140-6736(13)61221-0","article-title":"Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study","volume":"382","author":"Cahn","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.jcv.2018.06.012_bib0050","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1097\/QAI.0b013e31826bfd02","article-title":"The activity of the integrase inhibitor dolutegravir against HIV-1 variants isolated from raltegravir-treated adults","volume":"61","author":"Underwood","year":"2012","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.jcv.2018.06.012_bib0055","doi-asserted-by":"crossref","first-page":"11269","DOI":"10.1128\/JVI.01881-15","article-title":"The combination of the R263K and T66I resistance substitutions in HIV-1 integrase Is incompatible with High-level viral replication and the development of High-level drug resistance","volume":"89","author":"Liang","year":"2015","journal-title":"J. Virol."},{"issue":"24","key":"10.1016\/j.jcv.2018.06.012_bib0060","first-page":"132","article-title":"Update of the drug resistance mutations in HIV-1","volume":"2017","author":"Wensing","year":"2017","journal-title":"Top. Antivir. Med."},{"key":"10.1016\/j.jcv.2018.06.012_bib0065","doi-asserted-by":"crossref","first-page":"3080","DOI":"10.1093\/jac\/dkv243","article-title":"Integrase inhibitor (INI) genotypic resistance in treatment-naive and raltegravir-experienced patients infected with diverse HIV-1 clades","volume":"70","author":"Doyle","year":"2015","journal-title":"J Antimicrob. Chemother."},{"key":"10.1016\/j.jcv.2018.06.012_bib0070","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1093\/jac\/dkp252","article-title":"Rules-based HIV-1 genotypic resistance interpretation systems predict 8-week and 24-week virological antiretroviral treatment outcome and benefit from drug potency weighting","volume":"64","author":"Zazzi","year":"2009","journal-title":"J Antimicrob. Chemother."},{"key":"10.1016\/j.jcv.2018.06.012_bib0075","doi-asserted-by":"crossref","first-page":"343","DOI":"10.3851\/IMP2878","article-title":"Dolutegravir versus placebo in subjects harbouring HIV-1 with integrase inhibitor resistance associated substitutions: 48-week results from VIKING-4, a randomized study","volume":"20","author":"Akil","year":"2015","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.jcv.2018.06.012_bib0080","doi-asserted-by":"crossref","first-page":"E428","DOI":"10.1111\/j.1469-0691.2012.03917.x","article-title":"Prevalence of HIV-1 integrase mutations related to resistance to dolutegravir in raltegravir na\u00efve and pretreated patients","volume":"18","author":"Saladini","year":"2012","journal-title":"Clin. Microbiol. Infect."},{"key":"10.1016\/j.jcv.2018.06.012_bib0085","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1093\/jac\/dku535","article-title":"Cross-resistance to elvitegravir and dolutegravir in 502 patients failing on raltegravir: a French national study of raltegravir-experienced HIV-1-infected patients","volume":"70","author":"Fourati","year":"2015","journal-title":"J Antimicrob. Chemother."},{"key":"10.1016\/j.jcv.2018.06.012_bib0090","article-title":"Long-term efficacy of dolutegravir in treatment-experienced subjects failing therapy with HIV-1 integrase strand inhibitor-resistant virus","author":"Castagna","year":"2017","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.jcv.2018.06.012_bib0095","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1111\/1469-0691.12100","article-title":"Factors associated with virological success with raltegravir-containing regimens and prevalence of raltegravir-resistance-associated mutations at failure in the ARCA database","volume":"19","author":"Rusconi","year":"2013","journal-title":"Clin. Microbiol. Infect."},{"key":"10.1016\/j.jcv.2018.06.012_bib0100","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.jgar.2015.07.006","article-title":"Trends in drug resistance-associated mutations in a real-life cohort of Italian patients infected with HIV-1","volume":"3","author":"Montagna","year":"2015","journal-title":"J. Glob. Antimicrob. Resist."},{"issue":"31","key":"10.1016\/j.jcv.2018.06.012_bib0105","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1097\/QAD.0000000000001494","article-title":"Emergent drug resistance with integrase strand transfer inhibitor-based regimens","volume":"19","author":"Lepik","year":"2017","journal-title":"AIDS"},{"key":"10.1016\/j.jcv.2018.06.012_bib0110","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1093\/cid\/cit697","article-title":"Resistance to HIV integrase strand transfer inhibitors among clinical specimens in the United States, 2009-2012","volume":"58","author":"Hurt","year":"2014","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.jcv.2018.06.012_bib0115","doi-asserted-by":"crossref","first-page":"169","DOI":"10.3851\/IMP3082","article-title":"Dolutegravir monotherapy as treatment de-escalation in HIV-infected adults with virological control: DoluMono cohort results","volume":"22","author":"Oldenbuettel","year":"2017","journal-title":"Antivir. Ther."},{"issue":"17","key":"10.1016\/j.jcv.2018.06.012_bib0120","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1186\/s12879-017-2311-2","article-title":"Lamivudine\/dolutegravir dual therapy in HIV-infected, virologically suppressed patients","volume":"16","author":"Maggiolo","year":"2017","journal-title":"BMC Infect. Dis."},{"key":"10.1016\/j.jcv.2018.06.012_bib0125","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1097\/QCO.0b013e32835a1de7","article-title":"Emerging patterns and implications of HIV-1 integrase inhibitor resistance","volume":"25","author":"Geretti","year":"2012","journal-title":"Curr. Opin. Infect. Dis."},{"key":"10.1016\/j.jcv.2018.06.012_bib0130","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1093\/jac\/dkp423","article-title":"Integrase variability and susceptibility to HIV integrase inhibitors: impact of subtypes, antiretroviral experience and duration of HIV infection","volume":"65","author":"Garrido","year":"2010","journal-title":"J Antimicrob. Chemother."},{"key":"10.1016\/j.jcv.2018.06.012_bib0135","article-title":"French national survey of resistance to integrase inhibitors shows high differences of resistance selection rate in case of virological failure in a context of routine hospital care (ANRS-AC11 virology network), 23\u201326 October, Glasgow, UK. Abstract O332","author":"Marcelin","year":"2016","journal-title":"International Congress of Drug Therapy in HIV Infection."},{"key":"10.1016\/j.jcv.2018.06.012_bib0140","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.antiviral.2015.04.014","article-title":"Natural polymorphism S119R of HIV-1 integrase enhances primary INSTI resistance","volume":"119","author":"Hachiya","year":"2015","journal-title":"Antivir. Res."},{"key":"10.1016\/j.jcv.2018.06.012_bib0145","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1093\/jac\/dkv012","article-title":"Non-virological response to a dolutegravir-containing regimen in a patient harbouring a E157Q-mutated virus in the integrase region","volume":"70","author":"Danion","year":"2015","journal-title":"J Antimicrob. Chemother."},{"key":"10.1016\/j.jcv.2018.06.012_bib0150","first-page":"1537","article-title":"Ultradeep sequencing detection of the R263K integrase inhibitor drug resistance mutation","volume":"72","author":"Jaffr\u00e9","year":"2017","journal-title":"J Antimicrob. Chemother."},{"key":"10.1016\/j.jcv.2018.06.012_bib0155","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1097\/QAD.0000000000001616","article-title":"The HIV-1 integrase E157Q polymorphism per se does not alter susceptibility to raltegravir and dolutegravir in vitro","volume":"31","author":"Saladini","year":"2017","journal-title":"AIDS"}],"container-title":["Journal of Clinical Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1386653218301628?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1386653218301628?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,8,26]],"date-time":"2022-08-26T03:53:35Z","timestamp":1661486015000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1386653218301628"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":31,"alternative-id":["S1386653218301628"],"URL":"https:\/\/doi.org\/10.1016\/j.jcv.2018.06.012","relation":{},"ISSN":["1386-6532"],"issn-type":[{"value":"1386-6532","type":"print"}],"subject":[],"published":{"date-parts":[[2018,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dolutegravir (DTG)-containing regimens after receiving raltegravir (RAL) or elvitegravir (EVG): Durability and virological response in a large Italian HIV drug resistance network (ARCA)","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Virology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcv.2018.06.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}